Profile data is unavailable for this security.
About the company
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
- Revenue in USD (TTM)408.81m
- Net income in USD-1.71m
- Incorporated2012
- Employees797.00
- LocationAxonics Inc26 Technology DriveIRVINE 92618United StatesUSA
- Phone+1 (949) 396-6322
- Fax+1 (949) 396-6321
- Websitehttps://www.axonics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enovis Corp | 1.91bn | -107.11m | 2.44bn | 6.55k | -- | 0.7286 | 16.86 | 1.27 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Myriad Genetics, Inc. | 802.20m | -155.20m | 2.59bn | 2.70k | -- | 3.49 | -- | 3.22 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Inari Medical Inc | 547.47m | -57.05m | 2.59bn | 1.30k | -- | 6.09 | -- | 4.72 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| UFP Technologies Inc | 417.47m | 49.55m | 2.59bn | 3.09k | 52.72 | 8.36 | 42.26 | 6.21 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| 10X Genomics Inc | 631.73m | -239.78m | 2.66bn | 1.26k | -- | 3.67 | -- | 4.21 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| LivaNova PLC | 1.21bn | -16.59m | 2.77bn | 2.90k | -- | 2.23 | 92.45 | 2.29 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.79bn | 2.40k | -- | 11.93 | -- | 3.51 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Quidelortho Corp | 2.83bn | -1.86bn | 3.11bn | 7.10k | -- | 0.9775 | -- | 1.10 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| Envista Holdings Corp | 2.53bn | -1.32bn | 3.30bn | 12.80k | -- | 1.11 | -- | 1.30 | -7.70 | -7.70 | 14.64 | 17.32 | 0.4207 | 4.08 | 6.37 | 197,937.50 | -21.98 | 1.94 | -26.29 | 2.34 | 54.89 | 57.65 | -52.25 | 5.29 | 1.90 | 3.92 | 0.3357 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
| Axonics Inc | 408.81m | -1.71m | 3.51bn | 797.00 | -- | 5.45 | 323.67 | 8.59 | -0.0291 | -0.0291 | 8.11 | 12.61 | 0.5856 | 1.12 | 7.81 | 512,934.80 | -0.2451 | -12.67 | -0.2618 | -13.76 | 75.89 | 70.04 | -0.4185 | -29.68 | 7.11 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
| Evolent Health Inc | 2.35bn | -106.20m | 3.59bn | 4.70k | -- | 3.36 | 234.28 | 1.52 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
| Neogen Corp | 924.22m | -9.42m | 3.74bn | 2.92k | -- | 1.19 | 34.82 | 4.04 | -0.0435 | -0.0435 | 4.27 | 14.51 | 0.203 | 2.85 | 5.67 | 316,839.90 | -0.207 | 1.38 | -0.214 | 1.44 | 50.19 | 48.23 | -1.02 | 4.31 | 2.59 | 1.19 | 0.2208 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
| Haemonetics Corporation | 1.33bn | 114.89m | 3.87bn | 3.66k | 33.87 | 4.27 | 17.73 | 2.90 | 2.23 | 2.23 | 25.92 | 17.70 | 0.5924 | 1.87 | 7.05 | 364,751.20 | 5.10 | 5.02 | 5.74 | 6.07 | 53.58 | 51.74 | 8.61 | 8.11 | 2.33 | 60.20 | 0.5747 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
| Procept Biorobotics Corp | 176.58m | -103.71m | 4.27bn | 626.00 | -- | 17.10 | -- | 24.16 | -2.06 | -2.06 | 3.50 | 4.85 | 0.546 | 1.85 | 3.83 | 282,068.70 | -32.07 | -- | -36.52 | -- | 54.73 | -- | -58.73 | -- | 6.49 | -- | 0.1696 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Integer Holdings Corp | 1.67bn | 105.37m | 4.30bn | 10.50k | 42.11 | 2.77 | 20.59 | 2.58 | 3.05 | 3.05 | 48.27 | 46.34 | 0.5574 | 4.88 | 5.10 | 158,938.20 | 3.52 | 3.28 | 3.78 | 3.53 | 26.77 | 26.94 | 6.31 | 6.40 | 1.96 | 3.67 | 0.4215 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
| ICU Medical Inc | 2.30bn | -70.79m | 4.30bn | 14.00k | -- | 2.11 | 27.45 | 1.87 | -2.92 | -2.92 | 94.90 | 83.43 | 0.5267 | 2.13 | 14.68 | 164,591.20 | -1.62 | 1.46 | -1.83 | 1.65 | 32.47 | 34.11 | -3.07 | 2.23 | 1.08 | 0.5555 | 0.4412 | 0.00 | -0.9154 | 10.04 | 60.08 | -- | -1.45 | -- |
Data as of Sep 19 2024. Currency figures normalised to Axonics Inc's reporting currency: US Dollar USD
40.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.89m | 9.57% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.76m | 7.35% |
| Alpine Associates Management, Inc.as of 30 Jun 2024 | 2.11m | 4.13% |
| Fidelity Investments Canada ULCas of 30 Jun 2024 | 2.04m | 3.99% |
| Soros Fund Management LLCas of 30 Jun 2024 | 1.77m | 3.47% |
| Westchester Capital Management LLCas of 30 Jun 2024 | 1.35m | 2.65% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.27m | 2.49% |
| Mackenzie Financial Corp.as of 30 Jun 2024 | 1.26m | 2.47% |
| Kryger Capital Ltd.as of 30 Jun 2024 | 1.22m | 2.39% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.21m | 2.37% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
